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Abstract: Intervertebral disc degeneration often requires bony spinal fusion for long-term relief. 
Current arthrodesis procedures use bone grafts from autogenous bone, allogenic backed bone, 
or synthetic materials. Autogenous bone grafts can result in donor site morbidity and pain at 
the donor site, while allogenic backed bone and synthetic materials have variable effectiveness. 
Given these limitations, researchers have focused on new treatments that will allow for safe and 
successful bone repair and regeneration. Mesenchymal stem cells have received attention for their 
ability to differentiate into osteoblasts, cells that synthesize new bone. With the recent advances 
in scaffold and biomaterial technology as well as stem cell manipulation and transplantation, 
stem cells and their scaffolds are uniquely positioned to bring about significant improvements 
in the treatment and outcomes of spinal fusion and other injuries.
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Introduction
Intervertebral disc degeneration remains a pervasive and intractable disease arising 
from a combination of aging and stress on the bony and cartilaginous elements of the 
spinal column.1 Some patients will have disease progression that, despite conservative 
and minimally invasive therapies, requires arthrodesis (fusion) of particular spinal 
segments as the direct treatment of pathological pain-generating motion, or in 
stabilization after the decompression of symptomatic neural elements. As spinal 
instrumentation has evolved over the last decade, the role that surgery plays in the 
treatment of degenerative spinal pathology has increased. Critical to achieving a 
durable repair of the spine, arthrodesis depends heavily on the quality and quantity 
of autograft bone or bone substitutes. The ideal bone graft substitute should provide 
the benefits afforded by autograft (successful physiological fusion), thus allowing 
surgical intervention to be successful without the risk of donor site morbidity from 
autograft harvesting.
Regenerative medicine attempts to repair, regenerate, or replace tissues damaged 
by factors such as injury or disease.2 This growing field of medicine brings the promise 
of stem cells in the improvement of fusion options. In this pursuit, advancements 
in osteogenesis through the use of mesenchymal stem cells (MSCs) may provide 
the fundamental components that comprise autograft: osteoconductive scaffolds, 
osteoinductive signals, and osteogenic cells. Given the recent advances in minimally 
invasive spine surgery and the developing body of work on stem cell manipulation Biologics: Targets and Therapy 2012:6 submit your manuscript | www.dovepress.com
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and transplantation, stem cells are uniquely poised to bring 
about large-scale improvements in treatment and outcomes 
of spinal fusion and other injuries. However, there are 
fundamental unresolved issues in the therapeutic use of 
stems cells; namely, the percentage and quantity of cells that 
are phenotypically MSCs remain to be discovered. These 
cells are most likely the “engine” that makes the bone heal. 
Essential to providing evidence toward the efficacy of MSC-
mediated osteogenesis and bone healing is the evaluation 
of the gene expression profile and protein determination of 
MSCs and their cellular osteogenic progeny.
Natural bone healing cascade
Osteogenesis occurs throughout life, is involved in bone 
remodeling in adults, and is activated in injuries including, 
but not limited to, fractures of the bone.3,4 Bone formation 
depends on the cooperation of four factors: (1) specific cell 
types such as MSCs, osteoblasts, and osteoclasts; (2) the 
scaffold (hydroxyapatite, extracellular matrix molecules); 
(3) expression of soluble molecules (cytokines, growth 
factors, hormones, ions, vitamins);3,5,6 and (4) various 
mechanical stimuli.3,7 Normal development of the skeleton 
during embryogenesis occurs by intramembranous and 
endochondral ossification.3,8
Osteoblasts secrete the growth factors and deposit the 
matrix necessary for osteogenesis, while osteoclasts function 
in bone remodeling.9 Skeletal stability is reached by focal 
osteoclast-mediated degradation and osteoblast-mediated 
formation, while the overall architecture and anatomy of 
bones is maintained. Thus, the amount of new bone equals the 
amount resorbed, with no net change in the volume of bone.10 
As a consequence, new calcium phosphate crystals replace 
the less soluble and mature mineral crystalline component of 
bone.10 Therefore, the molecular remodeling and composition 
of the adult skeleton is a dynamic process that changes as a 
new bone fills each resorbed site.10 Moreover, the renewal 
of bone matrix is central for the essential role that bone has 
in mineral exchange and homeostasis.10
The MSC component
In the adult stages, MSCs contribute to the maintenance of 
various tissues, particularly those of the bone.3 MSCs can 
be isolated from bone marrow and adipose tissues in adult 
stages and from placenta and umbilical cord blood.3,11 MSCs 
can be induced in vitro and in vivo to differentiate into vari-
ous mesenchymal tissues such as bone, cartilage, muscle, 
tendon, adipose tissue, and hematopoiesis-supporting stro-
ma.3 MSCs are selected by their capacity for adherence to 
plastic culture flasks and then expand via colony-forming 
unit fibroblasts after several weeks in vitro.3,11 However, 
this procedure does not permit characterization of the 
native form, whereas extensive work has described the in 
vitro-derived phenotype and multipotentiality of cultured 
MSCs.3 Recent studies have clearly demonstrated that 
native-form MSCs are phenotypically and functionally 
different from cultured MSCs and similar to perivascular 
cells.3 Under in vitro conditions, cultured MSCs can be 
characterized as nonhematopoietic cells (CD14-, CD34-, 
and CD45-) and express several surface markers such as 
CD44, CD106, CD146, and CD166.3 Cultured MSCs are 
largely used in experimental bone reconstruction in vivo 
and in vitro.3,11,12 The cells are generally cultured in basal 
medium such as Dulbecco’s modified Eagle’s medium 
with 10% fetal bovine serum.11,13 Researchers believe that 
serum components in fetal bovine serum play crucial roles 
in the attachment and proliferation of MSCs.14 Osteogenic 
activation requires the presence of β-glycerol-phosphate, 
L-ascorbic acid-2 phosphate, dexamethasone, and fetal 
bovine serum.13,15 A study by Jaiswal et al found that optimal 
osteogenic differentiation was achieved with Dulbecco’s 
modified Eagle’s medium-base medium plus 100 nM 
dexamethasone, 0.05 mM L-ascorbic acid-2 phosphate, and 
10 mM β-glycerol-phosphate.15 Although few human clinical 
studies have investigated improvements in either bone 
defects or osteogenesis imperfecta disease,   clinical studies, 
with related controls, are needed to   confirm the potential of 
cultured MSCs, regardless of origin (allogeneic or autolo-
gous), for use in bone tissue engineering in the clinic.3
MSC derivation
The limiting factor in exploiting stem cells for therapeutic 
use is obtaining well characterized cells for transplantation.1 
Several researchers have demonstrated that colonies derived 
from colony-forming unit fibroblast assays are heterogeneous 
in appearance and size as well as differentiation potential.16–18 
Studying the activity of MSCs is made difficult by the lack of 
unique identifying markers, and therefore an inconsistency 
in molecular expression.2,19–21 Consequently, directing the 
appropriate differentiation of both native-form MSCs and 
cultured MSCs is a complex molecular and cellular riddle 
that is dependent upon not only the inherent   properties of 
cells but also the environment in which they are cultured.1 
The soluble growth factors, transforming growth factor beta 
and bone morphogenetic proteins (BMPs), are the necessary 
components of in vitro culture media used to induce 
chondrogenic and osteogenic differentiation of MSCs.1 Biologics: Targets and Therapy 2012:6 submit your manuscript | www.dovepress.com
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In fact, careful use of soluble factors in media can lead 
to chondrogenesis and osteogenesis with a genetic profile 
similar to intervertebral disc tissue, rather than articular 
cartilage.1,22
Another method exploits the MSCs’ microenvironment 
and triggers differentiation by coculturing with different 
cell populations to take advantage of cell–cell contact and 
activation.1 Utilizing the autocrine and paracrine factors 
secreted by one cell type leads to the activation of cell surface 
receptors on MSCs.1 Experiments culturing human neural 
progenitor cells and MSCs found that differentiation was 
reliant on cell–cell contact by looking at gene expression of 
Sox9, type II collagen, and aggrecan.1,23
The three-dimensional properties of the culture system 
have also been shown to exert substantial influence on the 
process of cell fate determination.1 MSCs are pelleted down 
into a dense micromass in combination with transforming 
growth factor, BMP, and insulin-like growth factor growth 
factors,9 before addition of soluble factors to recreate the in 
vivo state that leads to cartilage formation.1 This   structure 
helps direct the chondrogenic cascade of MSC differentiation 
from micromass into cartilage.1 Mesenchymal   condensation 
allows for extracellular signaling molecules, such as Wnt 
glycoproteins and N-cadherin, to form cadherin and con-
nexin adhesion complexes for the beginning stages of 
extracellular matrix formation.1 Cartilage then begins to 
form on this three-dimensional scaffold.1 Plating density 
of MSCs prior to soluble factor addition also influences the 
efficiency of differentiation.1 This is because plating density 
can change the cell morphology; specifically, wider spindle-
shaped cells correspond with denser MSCs plating.1 Wider 
cells also have an increased propensity to differentiate after 
exposure to soluble factors in vitro.1,24 In this way, employing 
density-dependent culturing techniques can produce cartilage 
formation from MSCs in vitro, and increase the efficiency 
of MSC differentiation.1
It has been suggested that MSCs can be isolated from 
other tissues, but their similarity to those isolated from bone 
marrow in terms of potential for osteogenesis and chondro-
genesis is not fully understood. Controversial cells from 
human umbilical cord blood and human derived-placenta 
cells have been extensively studied for MSC potential. An 
early study identified preterm cord blood as being rich in 
mesenchymal progenitor cells that displayed a fibroblast-like 
morphology and expressed several mesenchymal progenitor 
cell-related surface antigens.25 Another group later isolated 
human MSC-like adherent cells from human umbilical cord 
blood that could differentiate into a variety of mesenchymal 
lineage cells, including osteoblasts and chondrocytes, under 
the appropriate conditions.26 A related study identified MSC-
like cells in human placenta that possessed multilineage 
differentiation potential similar to MSCs under specific 
conditions.27 The less-controversial adipose tissue-derived 
MSCs have been previously shown to differentiate into 
bone, cartilage, fat, or muscle but have been found to have an 
inferior potential for both osteogenesis and chondrogenesis 
compared with bone marrow-derived MSCs.28
Molecular mechanisms underlying 
bone healing
Osteoblasts are cells of mesenchymal origin that secrete 
bone-matrix proteins and promote mineralization.29–31 The 
proliferation and differentiation of osteoblasts are under 
the control of a number of soluble factors and transcription 
factors such as runt-related transcription factor 2 (Runx2) 
and osterix (also known as Sp7).29,32,33 Differentiated 
osteoblasts embedded in the bone matrix are called 
osteocytes and might have a specific, but currently unclear, 
role in mechanotransduction.29,30 Osteoclasts are cells of 
hematopoietic origin that decalcify and degrade the bone 
matrix by acid decalcification and proteolytic degradation, 
respectively.29,34 They are large, multinucleated cells formed 
by the fusion of precursor cells of the monocyte–macrophage 
lineage.29
In vitro osteoclast differentiation is supported by 
mesenchymal cells (bone marrow stromal cells or osteoblasts) 
through cell–cell contact,29,35 although there has been little in 
vivo information about osteoclastogenesis-supporting cells.29 
Osteoclastogenic signals are mediated by receptor activator 
of nuclear kappa-B ligand (RANKL) and its costimulatory 
signals, in addition to macrophage colony-stimulating 
factor 5 (Figure 1).29,36–38 The congenital lack of osteoclasts 
leads to osteopetrosis, which is characterized by a high bone 
mass and a defect in bone marrow formation.29 Naturally 
occurring mutant mice or genetically modified mice with 
osteopetrosis have provided insights into the molecular 
mechanism of osteoclast differentiation and function.29,39 
Macrophage colony-stimulating factor and the transcription 
factor PU.1 are crucial for the proliferation and survival 
of osteoclast precursor cells; transcription factors such as 
cFOS, microphthalmia-associated transcription factor, and 
nuclear factor kappa-B have been shown to be essential for 
osteoclast differentiation; and factors such as cSRC, VAV3, 
β3-integrin, chloride-channel family member ClC7, vacuolar 
adenosine triphosphatase, and cathepsin K are crucial for 
osteoclast function (Figure 2).29,39Biologics: Targets and Therapy 2012:6 submit your manuscript | www.dovepress.com
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Therefore, for bone remodeling after fracture, MSCs 
are recruited within lesions and induced to form new bone 
via both endochondral and intramembranous   ossification.3 
Whether healing of a fracture or other injury occurs   following 
an endochondral or intramembranous pathway is dependent 
on the sensitivity to the mechanical environment to which the 
injury is subjected.2 During bone formation, Indian hedge-
hog (Ihh) acts at a very early stage to induce the expression 
of Runx2, which needs to be phosphorylated to be active.3 
BMPs are also necessary to lead osteoblastic commitment 
and to drive osteoblastic maturation, notably through Runx2 
and distal-less homeobox 5 protein (Dlx5) induction.3 
Mitogen-activated protein kinase can phosphorylate Dlx5 
and Runx2.3 The osteochondroblastic progenitors can express 
Ihh, which induces secretion of parathyroid hormone (PTH)-
related protein and acts on preosteoblastic cells (positive 
for collagen 1a1, alkaline phosphatase, and PTH receptor 1 
(PTH-R1) to increase their maturation.3 Msh homeobox 2 
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Figure 1 Osteoclast differentiation is induced by macrophage colony-stimulating factor (M-CSF), receptor activator of nuclear factor-κB [NF-κB] ligand (RANKL) and its 
costimulatory factor, immunoglobulin (ig)-like receptor. (A) Precursor-cell stage. The binding of M-CSF to its receptor, cFMS, activates the proliferation and survival of 
osteoclast precursor cells of the monocyte–macrophage lineage that express receptor activator of nuclear factor-κB (RANK). The costimulatory receptors might be stimulated 
from early stages, although ligands of costimulatory receptors have yet to be identified. (B) Proximal RANK signals. RANKL binding to RANK results in the recruitment 
of tumor-necrosis-factor-receptor-associated factor 6 (TRAF6). At the same time, RANK activation results in the phosphorylation of the immunoreceptor tyrosine-based 
activation motif (iTAM) in DAP12 and Fc-receptor common γ-subunit (FcRγ), both of which are adaptor proteins associating with distinct ig-like receptors. ig-like receptor 
signals are called costimulatory signals for RANK. (C) initial induction of nuclear factor of activated T cells, cytoplasmic 1 (NFATc1). NFATc1, a key transcription factor for 
osteoclastogenesis, is initially induced by TRAF6-activated NF-κB and NFATc2 that is present in the cell before RANKL stimulation. Phosphorylation of the iTAM in DAP12 
(or FcRγ) results in the recruitment of spleen tyrosine kinases (SYKs) that activate calcium signaling through phospholipase Cγ (PLCγ). (D) Auto amplification of NFATc1. 
Calcium signal–mediated persistent activation of NFATc1, as well as cooperation with activator protein 1 (AP1), is a prerequisite for the robust induction of NFATc1. AP1 
activation is mediated by the induction and activation of cFOS by calcium/calmodulin-dependent protein kinase type iv (CaMKiv)-stimulated cyclic adenosine monophosphate 
responsive-element-binding protein (CReB) and cFMS. The NFATc1 promoter is epigenetically activated through histone acetylation and NFATc1 binds to an NFAT-binding 
site of its own promoter. (E) in the nucleus, NFATc1 works together with other transcription factors, such as AP1, PU.1, microphthalmia-associated transcription factor 
(MITF) and CREB, to induce various osteoclast-specific genes, including tartrate-resistant acid phosphatase, cathepsin K, and calcitonin receptor.
Note: Reprinted by permission from Macmillan Publishers Ltd: Nature Review Immunology, H Takayanagi, Osteoimmunology: shared mechanisms and crosstalk between the 
immune and bone systems, 7(4):292–304, copyright 2007.29Biologics: Targets and Therapy 2012:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
51
Stem cell-mediated osteogenesis
(Msx2) is a factor preferentially found within proliferative 
progenitors, whereas Dlx5 leads to maturation.3 In addition, 
Dlx5 and Msx2   compete for DNA binding.3 Therefore, the 
Dlx5:Msx2 content drives the maturation of cells.3 In   addition, 
Msx2 induces apoptosis in later stages of maturation.3 Wnt 
proteins can induce the proliferation of osteochondroblastic 
progenitors and preosteoblasts.3 When osteoblasts mature, they 
can express Wnt inhibitors such as Dickkopf-related protein 
1 molecules.3 Osteoclasts are capable of degrading mineralized 
bone and are hematopoietic-derived cells.3 They are gener-
ated through RANKL and macrophage colony-stimulating 
factor cytokines secreted by activated T- and B-lymphocytes 
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Figure 2 The immune and skeletal systems share cytokines, receptors, signaling molecules, and transcription factors, all of which cooperatively regulate osteoclasts 
and osteoblasts as well as their interactions. Osteoblasts regulate osteoclastogenesis through receptor activator of nuclear factor-κB (NF-κB) ligand (RANKL)-receptor 
activator of nuclear factor-κB (RANK) (and its decoy receptor osteoprotegerin [OPG]) interactions, macrophage colony-stimulating factor (M-CSF)–cFMS interactions and 
immunoglobulin (ig)-like receptors associated with immunoreceptor tyrosine-based activation motif-harboring adaptor molecules (such as DAP12 and Fc-receptor common 
γ-subunit [FcRγ], the ligands of which are not well characterized). Although not depicted, semaphorin 6D, and its receptor plexin A1, and ephrin receptor B4 and ephrin 
B2 were newly identified as mediators of osteoblast–osteoclast interactions. There are extensive signaling pathways in osteoclasts. RANK and Ig-like receptors stimulate 
downstream signaling cascades (such as tumor necrosis factor [TNF] receptor-associated factor 6 [TRAF6], NF-κB, mitogen-activated protein kinases [MAPKs], activator 
protein 1 [AP1], calcineurin, and nuclear factor of activated T cells cytoplasmic 1 [NFATc1]), which are influenced by a number of immunoregulatory molecules including 
CD40 ligand (CD40L), interleukin-1 (iL-1), interferon-β (iFNβ), iFNγ, TNF, and lipopolysaccharide (LPS). Dendritic-cell-specific transmembrane protein (DC-STAMP) and 
ATP6v0D2 are necessary for the fusion of osteoclast precursor cells. Phosphoinositide 3-kinase (Pi3K)-AKT and growth-factor-receptor-bound protein 2–extracellular-
signal-regulated kinase (GRB2–eRK) pathways are important for the proliferation and survival of the osteoclast lineage, whereas vAv3, cSRC, and Casitas B-lineage lymphoma 
(cCBL) are included in the molecules required for cytoskeletal reorganization and bone-resorbing osteoclasts. Osteoclast activity is dependent on acidifying proton pump 
ATP6i and chloride channel 7 (ClC7), as well as matrix-degrading enzymes such as cathepsin K and matrix metalloproteinase 9 (MMP9). The following molecules are known to 
be involved in both the bone system and the immune system: NF-κB, RANKL, RANK, OPG, cFMS, M-CSF, ig-like receptors, FcRγ, DAP12, TRAF6, MAPKs, AP1, calcineurin, 
NFATc1, CD40L, iL-1, iFNγ, iFNβ, TNF, LPS, DC-STAMP, Pi3K, AKT, eRK, vAv3, cSRC, and cCBL.
Note: Reprinted by permission from Macmillan Publishers Ltd: Nature Review Immunology, H Takayanagi, Osteoimmunology: shared mechanisms and crosstalk between the 
immune and bone systems, 7(4):292–304, copyright 2007.29
Abbreviations:  CaMKiv,  calcium/calmodulin-dependent  protein  kinase  type  iv;  CReB,  cyclic  adenosine  monophosphate  responsive-element-binding  protein;  PLC, 
phospholipase C; MiTF, microphthalmia-associated transcription factor; iKK, inhibitor of NF-κB (iκB) kinase; SYK, spleen tyrosine kinase.Biologics: Targets and Therapy 2012:6 submit your manuscript | www.dovepress.com
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and by preosteoblasts.3 Osteoclast activities can be regulated 
by interleukin-10 and by osteoprotegerin, a decoy receptor 
of RANKL.3 Osteoprotegerin is preferentially expressed by 
mature osteoblasts (positive for osteocalcin; bone sialoprotein; 
PTH-R1; and osteonectin, also referred to as SPARC).3 Finally, 
degradation of the bone matrix releases several cytokines and 
growth factors, such as BMPs and insulin-like growth factor, 
which in turn can activate immature cells (Figure 3).3
Scaffolds
While supporting osteogenesis and osteoconduction, an 
ideal scaffold should also provide mechanical stability 
and   support the necessary cell activity that leads to bone 
regrowth.2 Important scaffold properties to consider 
include   porosity, pore size, geometry, and material. 
Adequate porosity is essential for the infiltration of cells 
and the formation of blood vessels at the new bone.40 
BMPs
TGFβ
Col1a1+, ALP+
PTH-R1+
Osx Osx
OSC+, BSP+
PTH-R1+, SPARC+
Dlx5+
Msx2++
Sox9,5,6
Col2a1 Col10a1 PPARg
C/EBPa
Ebf-1
Apoptosis
Dlx5−
Runx2−
Dlx5
Msx2
C-fms
Bone
BMPs, IGF
Committed
pre-osteoblast
Ihh pathway
Ptch, Smo, GSK3β
Wnt canonical pathway
GSK3β, β-Catenin
Smad pathway
Alk, Smad1, 5, 8/Smad4
Mature
osteoblast
Osteoclast
TRAP+
CD14+
monocyte
Osteo-
chondroblast
progenitor
Mesenchymal
stem cells
Adipocyte
Immature
chondroblast
Chondroblast
Osteocyte
B lymphocytes
+ activated T cells
Ihh
PTHrP
Ihh
Wnt
Dkk1
RANKL
OPG
M-CSF
IL-10
MAPK
Runx2
Figure 3 Bone remodeling after fracture. Mesenchymal stem cells are recruited within lesions and induced to form new bone following both endochondral and 
intramembranous pathways. During bone formation, indian hedgehog (ihh) acts at a very early stage to induce the expression of runt-related transcription factor 2 (Runx2), 
which needs to be phosphorylated to be active. Bone morphogenetic proteins (BMPs) are also necessary to lead osteoblastic commitment and to drive osteoblastic 
maturation, notably through Runx2 and distal-less homeobox 5 (Dlx5) induction. Mitogen-activated protein kinase (MAPK) can phosphorylate Dlx5 and Runx2. The 
osteochondroblastic progenitors can express ihh, which induces secretion of parathyroid hormone-related protein (PTHrP) and also acts on preosteoblastic cells positive 
for collagen 1a1 (col1a1), alkaline phosphatase (ALP), and PTH receptor 1 (PTH-R1) to increase their maturation. Msh homeobox 2 (Msx2) is a factor preferentially found 
within proliferative progenitors, whereas Dlx5 leads to maturation. in addition, Dlx5 and Msx2 compete for DNA binding. Therefore, the Dlx5:Msx2 content drives the 
maturation of cells. in addition, Msx2 induces apoptosis in later stages of maturation. wnt proteins can induce the proliferation of osteochondroblastic progenitors and 
preosteoblasts. when osteoblasts mature, they can express wnt inhibitors such as Dickkopf-related protein 1 (Dkk1) molecules. Osteoclasts are capable of degrading 
mineralized bone and are hematopoietic-derived cells. They are generated through receptor activator of nuclear kappa-B ligand (RANKL) and macrophage colony-
stimulating factor (M-CSF) cytokines secreted by activated T- and B-lymphocytes and by preosteoblasts. Osteoclast activities can be regulated by interleukin-10 (iL-10) and 
by osteoprotegerin (OPG), a decoy receptor of RANKL. OPG is preferentially expressed by mature osteoblasts (positive for osteocalcin [OSC], bone sialoprotein [BSP], 
PTH-R1, and osteonectin [SPARC]). Finally, degradation of the bone matrix releases several cytokines and growth factors, such as BMPs and insulin-like growth factor 
(iGF), which in turn can activate immature cells.
Note: Reprinted and modified by permission from Trends in Molecular Medicine, F Deschaseaux, L Sensebe, D Heymann, Mechanisms of bone repair and regeneration, vol. 
15, issue 9, Pages 417–429, Copyright 1999, with permission from elsevier.3
Abbreviations: TRAP, tartrate-resistant acid phosphatase; Osx, osterix; Col10a1/2a1/1a1, collagen 10a1/2a1/1a1; GSK3β, glycogen synthase kinase 3β; TGFβ, transforming 
growth factor β; PPARg, peroxisome proliferator-activated receptor gamma; C/eBPa, CCAAT-enhancer-binding protein alpha.Biologics: Targets and Therapy 2012:6 submit your manuscript | www.dovepress.com
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Previous experiments found improved in vivo osteogen-
esis by using BMP-2-loaded hydroxyapatite scaffolds 
with high porosity, which allowed for cell recruitment and 
vascularization.2,41,42
Scaffold geometry is another important factor for 
successful osteogenesis. It dictates cell adhesion, proliferation, 
and differentiation as well as nutrient and oxygen availability. 
An experiment by Kilian et al concluded that geometry is 
important for producing an osteogenic pathway.43 They found 
that geometric features that increase actomyosin contractility 
promote osteogenesis through Wnt signaling and other 
pathways.43 They also discovered that a stiff underlying 
matrix in MSC cultures led to enhanced osteogenesis, most 
likely because the environment closely resembled that of bone 
in vivo. The nature of the scaffold’s surface has important 
implications for bone tissue formation. The bone–implant 
interface has been shown to positively correlate with an 
increasing roughness of the implant surface.44 Similarly, 
surface microcavities on a scaffold were shown to support a 
more vigorous osteogenic response from dental pulp-derived 
stromal stem cells.45
When selecting the appropriate material for a scaffold, 
several elements need to be considered, such as the 
material’s composition, degradation rate, and the strength 
it affords the scaffold. Current options for materials are 
natural or synthetic polymers (ie, polytetrafluoroethylene), 
bioactive materials (ie, bioactive glass), and osteophilic 
materials such as hydroxyapatite ceramics or composites.46 
Animal studies have shown that the best procedure by which 
MSCs can induce bone formation is via an injection or 
implant with the use of a natural or synthetic scaffold.9,47,48 
The natural or synthetic polymers become encapsulated 
by fibrous tissue and their high molecular weight 
results in slower degradation and improved mechanical 
strength.46,47,49,50 The poly(lactic-co-glycolic acid) polymer 
is a popular scaffold choice as it is infrequently rejected 
and does not cause inflammation, therefore, it has excellent 
biocompatibility.45 Bioactive materials chemically modify 
the surface of bone by forming a layer of hydroxyapatite 
and bind directly to the bone.46,51 For this reason, their 
use is limited to nonbearing applications. Osteophilic 
materials can directly apposition themselves to bone given 
their biocompatibility and high protein-binding affinity.46 Both 
of these qualities make them good vehicles for drug delivery. 
However, their use is also restricted to non-load-bearing 
sites as they fail readily due to their brittleness.46,52 Collagen 
carriers used in conjunction with ceramics such as 
hydroxyapatite and β-tricalcium phosphate have been used 
to deliver BMP-7 in spinal fusion and have been shown to 
perform similarly to bone autografts.46,53
A scaffold’s degradation rate is determined by its 
chemical and structural properties as well as many in vivo 
factors including pH, temperature, ionic strength, and access 
to vasculature. However, degradation can be dangerous 
resulting in the release of acidic products and a decrease 
in local pH.46 This can cause inflammation and/or tissue 
necrosis, and eventual tissue dysfunction.46,54
To provide structural support and mechanical stability, 
a scaffold must mimic the strength and stiffness of bone. 
A scaffold that is too weak can fail to support the skeleton, 
while one that is too stiff can lead to stress shielding.46,52 
Stress shielding results when the scaffold absorbs the 
mechanical stress, but the host bone is not stimulated 
enough for bone formation to occur. Thus, bone resorption 
continues, resulting in potential lysis around the implant. 
The appropriate combination of soluble factors and 
biomaterials will result in the most efficient and effective 
tissue regeneration.
Clinical application of MSCs
Bone autografts have been used for centuries in reconstructive 
surgery, as well as in orthopedic surgery, as unvascularized 
free grafts. Also, they have been grafted with vessels that 
require microanastomosis to maintain cellular viability 
in the graft to facilitate osteogenesis. Bone marrow has 
been used in a similar way to autologous bone grafts, both 
containing osteoblast precursors.46 Autologous marrow can 
be aspirated from the iliac crest and injected percutaneously 
into osseous defects.46,55 In 2005, Hernigou et al successfully 
used bone marrow cells that were isolated during surgery and 
concentrated them prior to implantation.46,56 Colony-forming 
unit fibroblasts are in vitro adherent bone marrow cells that 
can form bone in vivo.46,57 Although single adherent cells 
can form colonies containing multiple lineages, including 
chondrocytes, osteoblasts, adipocytes, and fibroblasts,11,46 
these cells are not capable of extensive self-renewal and 
therefore are not bona fide MSCs.
In vitro osteogenesis has been thoroughly demonstrated 
in monolayer culture, three-dimensional scaffolds,46,58–62 
research with animal and human cells, and has been 
reviewed elsewhere for a variety of audiences and clinical 
subspecialties.20,46,63–66 A US Food and Drug Administration-
approved cell-based product for bone regeneration in the 
clinic remains unavailable. Currently, the Food and Drug 
Administration has approved only one product under the 
autologous cellular therapy category (Carticel®; Genzyme Biologics: Targets and Therapy 2012:6 submit your manuscript | www.dovepress.com
Dovepress 
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Corporation, Cambridge, MA), which is designated to be 
used only for articular cartilage repair.46
Therapeutic applications
MSCs show great promise for the treatment of disease and 
repair of injury. Their use has been explored in several 
physiological realms including cardiovascular repair, 
central nervous system or spinal cord injury, and bone and 
cartilage repair. Damaged myocardium has been an active 
experimental target for site-directed MSC therapy. In 2001, 
Orlic et al showed that locally delivered bone marrow cells 
can generate de novo myocardium, indicating a use for 
stem cells in treating coronary artery disease.67 Similarly, 
the delivery of bone marrow cells into the infarct zone 
in patients following myocardial infarction resulted in a 
dramatic improvement in global heart function.68 Following 
bone marrow transplantation, engraftment of bone marrow-
derived cardiomyocytes was observed in the adult heart.69 
While MSCs and other bone marrow cells have shown 
improvements in myocardial function in many animal models 
of acute myocardial infarction, the mechanism of their effect 
is still unknown.
The in vivo use of stem cell-based therapy has been 
demonstrated for treatment of central nervous system or 
spinal cord injury. Two studies using a rat model of spinal 
cord injury have shown neurologic improvement upon 
  site-directed application of MSCs.70,71 The MSCs are credited 
with the production of essential trophic factors, which not 
only promoted directed growth of new axons but also formed 
“guiding strands” that bridged the epicenter of injury.16
The most successful application of MSCs has been 
site-directed administration for repair of bone or cartilage. 
It is estimated that 1,600,000 bone grafts are performed 
every year to regenerate bone lost to trauma and disease, 
6% (96,000) of which are craniomaxillofacial in nature.72 
In a two-stage procedure, a composite MSC and a titanium/
hydroxyapatite scaffold was placed into a patient’s latissimus 
dorsi for 7 weeks before transplantation to replace a segment 
of mandible.46 Although the procedure was associated with 
a number of technical problems, such as fracture of the 
titanium mesh, partial infection, and necrosis, islands of 
bone formation and increased bone density were documented 
within the transplant.46,73 Also, iliac crest MSCs injected 
around dental implants have been shown to result in new bone 
formation and osseointegration of the implants.46,74 Expanded 
periosteal cells were used in the reconstruction of an 
avulsed phalanx with porous hydroxyapatite.46,75 Follow-up 
at 28 months indicated retention of implant volume and 
structure, and evidence of lamellar bone comprising 5% of 
the construct volume.46
There is some clinical experience of bone reconstruction 
with expanded human MSCs combined with scaffolds. MSCs 
implanted on hydroxyapatite/tricalcium phosphate scaffolds 
have accelerated bone formation when placed in craniofacial 
defects and critical long-bone defects in small and large 
animal systems.76–78 Constructs of expanded autologous 
MSCs in macroporous hydroxyapatite were used in three 
patients with large segmental bone defects.46,79,80 Fusion 
between the implant and host bone occurred 5–7 months 
after surgery, with restoration of pain-free function for 
6–7 years.46 A study by Horwitz et al demonstrated that 
allogenic bone marrow transplantation in children with 
osteogenesis imperfecta, a genetic bone disorder, resulted 
in engraftment of donor-derived MSCs and an increase in 
new bone formation.81
Future directions
The basic and preclinical research literature clearly indicates 
that the use of MSCs for the reconstruction and repair of bone 
is feasible. Problem areas, however, include cell numbers, 
an overreliance on existing scaffold materials, optimum 
delivery of the required factors, and the control of transgene 
expression. Other matters that need further attention include 
the elimination of fetal calf serum, untoward effects of 
expanding cell numbers, the commitment to or reversibility 
of the differentiated state, the endurance of the cells in vivo, 
vascularization, integration with the recipient bone, and the 
capacity to form bone and marrow structures in vivo.
Concerns about the relevance of in vitro studies and 
studies in immunodeficient animals have dampened 
enthusiasm about the role of bone tissue engineering in 
bone regeneration. It remains unclear whether the cost 
and complexity of cell-based tissue engineering would 
hamper its potential application for bone tissue. Moreover, 
the relevance of troubling data from mouse studies needs 
to be addressed. In one study, after slow initial growth, 
mouse MSCs suddenly proliferated rapidly and became 
tumorigenic.46,82 In other studies, the host-derived sarcomas 
developed around implants with MSCs;46,83 this was thought 
to be a result of the stimulation of lymphocyte expansion 
by MSCs and suppression of the host’s antitumor immune 
response.46 Paracrine secretions of MSCs, therefore, could 
represent a double-edged sword by both inhibiting allogeneic 
surveillance and by promoting tumor development. Of 
importance, however, is that, unlike most preparations 
of human MSCs, the mouse MSCs were prepared from Biologics: Targets and Therapy 2012:6 submit your manuscript | www.dovepress.com
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whole marrow and included adherent blood cells and 
other differentiated cells. A reassessment of circulating 
osteoblast progenitor cells and perivascular cells, and their 
contribution to bone repair, raises attractive ideas for the 
capitalization of inherent regenerative potential without the 
use of exogenous cells.
What is needed now is a greater understanding of 
inadequate responses to tissue injury and the potential for 
mobilizing innate pathways. Current thinking about   biologic, 
regenerative medicine reemphasizes the potential of 
“primed” materials for stimulating, enhancing, or controlling 
a tissue’s innate capacity for repair. Successful tissue 
regeneration will require the identification of tissues with 
the appropriate populations of cells, the best conditions for 
their ex vivo expansion, the optimal nature of the scaffolds 
and carriers used, and the development of suitable preclinical 
animal models. To optimize the therapeutic applications of 
MSCs, we must construct novel techniques that surpass the 
simple expansion and transplantation procedures currently 
in use.
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